/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Eagle Pharmaceuticals Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.275 -0.3989(-39.89%) EGRX at 04 Dec 2025 04:30 PM Drug Manufacturers - Specialty & Generic
Lowest Today 1.8
Highest Today 2.8
Today’s Open 2.78
Prev. Close 3.56
52 Week High 14.78
52 Week Low 1.80
Day’s Range: Low 1.8 High 2.8
52-Week Range: Low 1.80 High 14.78
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -93.87
5 year return -95.61
10 year return -

Institutional Holdings

Nantahala Capital Management, LLC 30.28

AIGH Capital Management, LLC 9.35

Citigroup Inc 7.73

AQR Capital Management LLC 5.38

Vanguard Group Inc 4.36

Vanguard Total Stock Mkt Idx Inv 2.84

BlackRock Inc 2.72

Bank of America Corp 2.51

Morgan Stanley - Brokerage Accounts 2.32

LSV Asset Management 2.28

Renaissance Technologies Corp 1.88

Two Sigma Advisers, LLC 1.73

Marshall Wace Asset Management Ltd 1.51

J. Goldman & Co LP 1.47

Assenagon Asset Management SA 1.43

Perceptive Advisors LLC 1.34

D. E. Shaw & Co LP 1.32

Millennium Management LLC 1.29

Vanguard Institutional Extnd Mkt Idx Tr 1.16

Two Sigma Investments LLC 1.03

Los Angeles Capital Management LLC 1.02

RBF LLC 0.99

Fidelity Small Cap Index 0.83

AQR Small Cap Multi-Style I 0.74

Invesco FTSE RAFI US 1500 Small-Mid ETF 0.64

Fidelity Extended Market Index 0.47

Schwab US Small-Cap ETF™ 0.39

Xtrackers Stoxx Global Div100 Swp ETF 1D 0.38

Vanguard Health Care ETF 0.31

RBC Microcap Value I 0.28

NT R2000 Value Index Fund - NL 0.27

iShares U.S. Small-Cap Eq Fac ETF 0.25

Bridgeway Ultra-Small Company Market 0.23

BlackRock Extended Equity Market K 0.20

NT R2000 Index Fund - NL 0.20

KLP AksjeGlobal Small Cap Flerfaktor P 0.19

iShares Micro-Cap ETF 0.18

Northern Trust Russell 2000 Value Index 0.16

NT R2000 Value Index Fund - L 0.16

NT R2000 Index Fund - DC - NL - 2 0.15

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 46.13 M

PB Ratio 0.1825

PE Ratio 4.1882

Enterprise Value 102.26 M

Total Assets 406.16 M

Volume 4664101

Company Financials

Annual Revenue FY22:316610000 316.6M, FY21:171546000 171.5M, FY20:187802000 187.8M, FY19:195892000 195.9M, FY18:213312000 213.3M

Annual Profit FY22:221674000 221.7M, FY21:129366000 129.4M, FY20:142337000 142.3M, FY19:134995000 135.0M, FY18:151396000 151.4M

Annual Net worth FY22:35642000 35.6M, FY21:-8627000 -8.6M, FY20:11989000 12.0M, FY19:14313000 14.3M, FY18:31903000 31.9M

Quarterly Revenue Q2/2023:64646000 64.6M, Q1/2023:66305000 66.3M, Q4/2022:60699000 60.7M, Q3/2022:65901000 65.9M, Q2/2022:74136000 74.1M

Quarterly Profit Q2/2023:47788000 47.8M, Q1/2023:49005000 49.0M, Q4/2022:40833000 40.8M, Q3/2022:42250000 42.3M, Q2/2022:50472000 50.5M

Quarterly Net worth Q2/2023:5164000 5.2M, Q1/2023:5750000 5.8M, Q4/2022:8165000 8.2M, Q3/2022:-3513000 -3.5M, Q2/2022:-9450000 -9.5M

Fund house & investment objective

Company Information Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Organisation Drug Manufacturers - Specialty & Generic

Employees 134

Industry Drug Manufacturers - Specialty & Generic

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow